TrumpRx.gov, the federal drug-price website that credits President Trump for its prices, lists 90 tablets of Sanofi’s blood thinner Plavix at $15.95, against an original price of $771.62. The site’s Presidential deals page, which it describes as deals negotiated by President Trump for brand-name drugs, shows the $15.95 figure next to a 98% discount tag, and the Plavix drug page shows a $755.67 saving on the 75 mg, 90-count configuration.
The prices appeared on the site on October 10, 2026. Anyone who buys at that price does so with a coupon presented at a pharmacy, not through a Medicare plan.
The people with the most reason to look closely are those who take clopidogrel, the drug in Plavix, and carry Medicare Part D coverage. The site itself says the figure is an out-of-pocket price and tells visitors with insurance to check their co-pay first because it “may be even lower.” For a Part D enrollee, the real question is whether $15.95 in cash for 90 tablets beats what the plan charges for the same fill, and what each route does to the year’s spending against the plan’s cap.
Part D enrollees weighing a $15.95 cash fill are doing it inside a 2026 out-of-pocket cap of $2,100 on covered drugs. The Medicare Cost & Coverage Protection Kit lays out the new Part D out-of-pocket cap and the 51 state Medicare cost-help packs for people who may get state help with drug costs.
What the TrumpRx listing shows
The Plavix page names Sanofi as the maker and lists the product as “Clopidogrel by Sanofi.” It offers one strength and one quantity, a 75 mg tablet in a 90-count supply. The $771.62 original price is the site’s own reference figure for that configuration, and the discount works out to 98%. The page says the coupon is presented at the pharmacy to claim the TrumpRx savings, and that the drug is widely supported at retail pharmacies that dispense Plavix. A photo on the browse page is labeled illustrative.
The pages do not carry a date. TrumpRx lists “Last updated unavailable” on the Plavix page, so $15.95 is what the site showed on October 10, and a price shown on a government website can change.
The site’s homepage promotes TrumpRx as offering “the lowest prescription prices in the world for Americans” and now carrying “hundreds of generics.” Its front page credits the president for the prices.
What 90 tablets at $15.95 means per dose
Clopidogrel is taken as a tablet once a day, according to the National Library of Medicine’s MedlinePlus drug information. At one tablet a day, 90 tablets is a 90-day supply, and $15.95 comes to about 18 cents a tablet. The $771.62 original price comes to roughly $8.57 a tablet on the same math.
The Food and Drug Administration calls Plavix a blood-thinning drug and describes clopidogrel as an antiplatelet medicine used to prevent blood clots in patients who have had a heart attack or stroke. MedlinePlus says it is used to prevent repeat heart attacks or strokes in people who have had a stroke, a heart attack, severe chest pain or peripheral arterial disease.
Where the Part D cap fits
Medicare Part D has an annual limit on what enrollees pay out of pocket for covered drugs. Medicare.gov gives the cap as $2,100 in 2026 and $2,400 in 2027. Once spending on covered Part D drugs reaches the limit, an enrollee moves into catastrophic coverage and pays nothing out of pocket for covered drugs for the rest of the calendar year.
Medicare lists what counts toward the limit: the 25% coinsurance paid in the initial coverage stage after any deductible, certain payments made on the enrollee’s behalf such as through Extra Help, and contributions from state pharmaceutical assistance programs. The same page describes the Medicare Prescription Payment Plan, which spreads covered out-of-pocket costs across the year, and says it does not save money or lower drug costs.
The TrumpRx listing is not a Medicare benefit, and the site’s own wording is that it is an out-of-pocket price. A Part D enrollee who expects a plan fill to count toward the cap should confirm with the plan how a coupon purchase is treated before choosing it.
A price comparison is not a reason to stop taking it
MedlinePlus is direct on one point: people should not change the amount or frequency of clopidogrel without talking to their doctor, and stopping it raises the risk of a heart attack or stroke. For people with a stent, stopping too soon can cause a clot to form in the stent. The medication also makes bleeding more likely, and MedlinePlus advises telling a doctor before combining it with aspirin or NSAIDs such as ibuprofen or naproxen.
Comparing the $15.95 Plavix price with a plan copay
The comparison takes three numbers. The first is the plan’s copay or coinsurance for a 90-day fill of Plavix or of generic clopidogrel, which the pharmacy or the plan’s pharmacy help line can quote. The second is the TrumpRx figure, which the TrumpRx site says is an out-of-pocket price. The third is where the year’s drug spending stands against the $2,100 cap, which the plan’s member portal or a recent explanation of benefits shows.
The site’s own advice is to check the co-pay first because it may be even lower. The plan’s number can come out higher or lower than $15.95, and for someone who has already reached the cap, covered drugs cost nothing for the rest of the year.
Medicare.gov’s drug cost page and the plan’s formulary are the places to verify tiers and coverage. A pharmacist can say what the plan charges for the brand and for generic clopidogrel.
A $15.95 fill against a $2,100 cap
The Medicare Cost & Coverage Protection Kit is a 15-page guide that covers the new Part D out-of-pocket cap and includes 51 state Medicare cost-help packs. Anyone weighing a coupon price against a plan copay has the cap and the state help to line up first, and the kit puts both in one place.
Get the Part D cap guide and your state’s Medicare cost-help pack →
This article was produced with AI assistance and reviewed by The Financial Wire’s editorial team.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
